Literature DB >> 24986203

Patient-reported outcomes are associated with patient-oncologist agreement of performance status in a multi-ethnic Asian population.

Chun Fan Lee1, Raymond Ng, Nan Luo, Yin Bun Cheung.   

Abstract

PURPOSE: This study aims to compare the performance status assessed by breast cancer patients and their oncologist and investigate the factors associated with the patient-oncologist disagreement in a multi-ethnic Asian population.
METHODS: This is a cross-sectional study of 270 female breast cancer patients in Singapore. Patients' performance status was rated by the patients and their treating oncologists. Patients were also asked to complete two instruments regarding their health status and health-related quality of life. The proportions of patients with assessment of performance status the same as and different from their oncologist were calculated. The level of agreement was quantified by Kappa statistics together with the confidence interval (CI). Multinomial logistic regression analyses were performed to examine potential factors associated with the patient-oncologist disagreement.
RESULTS: Approximately half (136/270) of the patients agreed with the oncologist in assessing performance status. Among the disagreeing half, 48 (17.8 %) patients rated better and 86 (31.9 %) poorer than the oncologists. The unweighted and quadratic-weighted Kappa statistics were, respectively, 0.21 (95 % CI = 0.13 to 0.29) and 0.34 (95 % CI = 0.26 to 0.42). Multivariable multinomial logistic regressions showed that outpatient, language used, and evidence of disease were associated with patients' better assessment than the oncologists, while age, physical well-being, and pain/discomfort were associated with patients' poorer assessment.
CONCLUSIONS: The patient-oncologist agreement was weak to moderate. When discrepant, patients tended to rate themselves worse than the oncologists assessed. Poorer assessment rated by patients was associated with their physical well-being. Patients who self-rated poorer may require further evaluation of any unobserved symptoms.

Entities:  

Mesh:

Year:  2014        PMID: 24986203     DOI: 10.1007/s00520-014-2336-7

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  13 in total

1.  The English and Chinese versions of the five-level EuroQoL Group's five-dimension questionnaire (EQ-5D) were valid and reliable and provided comparable scores in Asian breast cancer patients.

Authors:  Chun Fan Lee; Raymond Ng; Nan Luo; Nan Soon Wong; Yoon Sim Yap; Soo Kien Lo; Whay Kuang Chia; Alethea Yee; Lalit Krishna; Celest Wong; Cynthia Goh; Yin Bun Cheung
Journal:  Support Care Cancer       Date:  2012-06-06       Impact factor: 3.603

2.  Performance status assessment in cancer patients.

Authors:  C Conill; E Verger; M Salamero
Journal:  Cancer       Date:  1990-04-15       Impact factor: 6.860

3.  Toxicity and response criteria of the Eastern Cooperative Oncology Group.

Authors:  M M Oken; R H Creech; D C Tormey; J Horton; T E Davis; E T McFadden; P P Carbone
Journal:  Am J Clin Oncol       Date:  1982-12       Impact factor: 2.339

4.  Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument.

Authors:  M J Brady; D F Cella; F Mo; A E Bonomi; D S Tulsky; S R Lloyd; S Deasy; M Cobleigh; G Shiomoto
Journal:  J Clin Oncol       Date:  1997-03       Impact factor: 44.544

5.  Should patient-rated performance status affect treatment decisions in advanced lung cancer?

Authors:  Esther Dajczman; Goulnar Kasymjanova; Harvey Kreisman; Nelda Swinton; Carmela Pepe; David Small
Journal:  J Thorac Oncol       Date:  2008-10       Impact factor: 15.609

6.  Patient-physician disagreement regarding performance status is associated with worse survivorship in patients with advanced cancer.

Authors:  Ian D Schnadig; Erik K Fromme; Charles L Loprinzi; Jeff A Sloan; Motomi Mori; Hong Li; Tomasz M Beer
Journal:  Cancer       Date:  2008-10-15       Impact factor: 6.860

7.  Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L).

Authors:  M Herdman; C Gudex; A Lloyd; Mf Janssen; P Kind; D Parkin; G Bonsel; X Badia
Journal:  Qual Life Res       Date:  2011-04-09       Impact factor: 4.147

8.  Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer.

Authors:  M Ando; Y Ando; Y Hasegawa; K Shimokata; H Minami; K Wakai; Y Ohno; S Sakai
Journal:  Br J Cancer       Date:  2001-11-30       Impact factor: 7.640

9.  Discrepancy in patient-rated and oncologist-rated performance status on depression and anxiety in cancer: a prospective study protocol.

Authors:  Caryn Chan Mei Hsien; Wan Azmad Wan Azman; Mastura Md Yusof; Gwo Fuang Ho; Edward Krupat
Journal:  BMJ Open       Date:  2012-10-03       Impact factor: 2.692

10.  Performance status score: do patients and their oncologists agree?

Authors:  S P Blagden; S C Charman; L D Sharples; L R A Magee; D Gilligan
Journal:  Br J Cancer       Date:  2003-09-15       Impact factor: 7.640

View more
  3 in total

1.  Variability of performance status assessment between patients with hematologic malignancies and their physicians.

Authors:  Alexis D Leal; Cristine Allmer; Matthew J Maurer; Tait D Shanafelt; James R Cerhan; Brian K Link; Carrie A Thompson
Journal:  Leuk Lymphoma       Date:  2017-07-18

2.  Exploring the Score Equivalence of the English and Chinese Versions of the Brief Assessment Scale for Caregivers.

Authors:  Grace Meijuan Yang; Shirlyn Hui-Shan Neo; Irene Teo; Geok Ling Lee; Julian Thumboo; John Chia; Annie Lau; Audrey Koh; Debra Qu; William Wai Lam Che; Hwee Lin Wee; Myra Glajchen; Yin Bun Cheung
Journal:  J Patient Exp       Date:  2019-03-14

3.  Comparing assessment of diabetes-related quality of life between patients and their physicians.

Authors:  Orly Tamir; Nitzan Shabo De-Paz; David Dvir; Anthony D Heymann
Journal:  Health Qual Life Outcomes       Date:  2018-11-19       Impact factor: 3.186

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.